Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening Jul. 29, 2024 6:30 AM ...

The first blood test for colorectal cancer was approved Monday by the Food and Drug Administration. Guardant Health's Shield test is for people 45 and older who are at average risk for the disease.

Guardant Health’s Shield ™ blood test approved by FDA as a primary screening option, clearing path for Medicare reimbursement and a new era of colorectal cancer screening. News release.

On Monday, the FDA approved Guardant Health Inc.’s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.

Shield, made by Guardant Health, is the first approved blood test that is considered a primary screening option for the disease. The FDA has approved a new blood test for colorectal cancer.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s ...

Shield is a blood test from Guardant Health for colorectal cancer screening in average-risk individuals 45 and older. CREDIT: Business Wire/Guardant Health.

Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer Aug. 01, 2024 8:30 AM ET Guardant Health, Inc. (GH) ...

Guardant Health, Inc., a leading precision oncology company, today announced the U.S. Food and Drug Administration has approved the company’ s Shield™ blood test for colorectal cancer ...

PALO ALTO, Calif., July 29, 2024--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.

PALO ALTO, Calif., August 01, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield™ blood test, recently approved by the U.S. Food and ...